Drug-resistant tuberculosis medical therapy

Tuberculosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Tuberculosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Children
HIV Coinfection
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Special Conditions
Drug-resistant
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Drug-resistant tuberculosis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Drug-resistant tuberculosis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Drug-resistant tuberculosis medical therapy
CDC on Drug-resistant tuberculosis medical therapy
Drug-resistant tuberculosis medical therapy in the news
Blogs on Drug-resistant tuberculosis medical therapy
Directions to Hospitals Treating Tuberculosis
Risk calculators and risk factors for Drug-resistant tuberculosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Multiple Drug-Resistant (MDR) Tuberculosis

• MDR-TB is defined as resistance to isoniazid and rifampicin, with or without resistance to other first-line drugs.
• Medical treatment for MDR-TB consists of at least 4 drugs that have shown effectiveness against MDR.
• Treatment duration will depend on the culture results. The duration of therapy should be > 18 months after culture is negative.

MDR Tuberculosis   ▸  Adults   ▸  Children

MDR-TB Adults Standard Regimen Group 1: First-line oral drugs ▸ Pyrazinamide OR ▸ Ethambutol OR ▸ Rifabutin PLUS Group 2: Injectable drugs ▸ Kanamycin OR ▸ Amikacin OR ▸ Capreomycin OR ▸ Streptomycin PLUS Group 3: Fluoroquinolones ▸ Levofloxacin OR ▸ Moxifloxacin OR ▸ Ofloxacin PLUS Group 4:Oral bacteriostatic second-line drugs ▸ Para-aminosalicylic acid OR ▸ Cycloserine OR ▸ Terizidone OR ▸ Ethionamide OR ▸ Protionamide MDR-TB Children Preferred Regimen ▸

Extensively Drug-Resistant XDR Tuberculosis

XDR-TB is defined as resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables (amikacin, capreomycin, and kanamycin).

XDR Tuberculosis   ▸  Adults   ▸  Children

Non-Purulent Cellulitis - Adults Preferred Regimen ▸ ' Non-Purulent Cellulitis - Children Preferred Regimen ▸